These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 30725050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unexpected Anemia and Reticulocytopenia in an Adolescent With Sickle Cell Anemia Receiving Chronic Transfusion Therapy.
    Blauel ER, Grossmann LT, Vissa M, Miller ST.
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):e438-40. PubMed ID: 26207780
    [Abstract] [Full Text] [Related]

  • 3. Delayed hemolytic transfusion reaction presenting as a painful crisis in a patient with sickle cell anemia.
    Fabron A, Moreira G, Bordin JO.
    Sao Paulo Med J; 1999 Jan 07; 117(1):38-9. PubMed ID: 10413970
    [Abstract] [Full Text] [Related]

  • 4. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A.
    Hemoglobin; 2018 Jan 07; 42(5-6):339-341. PubMed ID: 30626228
    [Abstract] [Full Text] [Related]

  • 5. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.
    Pirenne F, Yazdanbakhsh K.
    Blood; 2018 Jun 21; 131(25):2773-2781. PubMed ID: 29724898
    [Abstract] [Full Text] [Related]

  • 6. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
    Reyes MA, Illoh OC.
    Immunohematology; 2008 Jun 21; 24(2):45-51. PubMed ID: 19852130
    [Abstract] [Full Text] [Related]

  • 7. A delayed hemolytic transfusion reaction due to anti-Cob.
    Squires JE, Larison PJ, Charles WT, Milner PF.
    Transfusion; 1985 Jun 21; 25(2):137-9. PubMed ID: 3984006
    [Abstract] [Full Text] [Related]

  • 8. Impact of Red Blood Cell Antigen Matching on Alloimmunization and Transfusion Complications in Patients with Sickle Cell Disease: A Systematic Review.
    Fasano RM, Meyer EK, Branscomb J, White MS, Gibson RW, Eckman JR.
    Transfus Med Rev; 2019 Jan 21; 33(1):12-23. PubMed ID: 30122266
    [Abstract] [Full Text] [Related]

  • 9. Delayed hemolytic transfusion reaction in children with sickle cell disease.
    de Montalembert M, Dumont MD, Heilbronner C, Brousse V, Charrara O, Pellegrino B, Piguet C, Soussan V, Noizat-Pirenne F.
    Haematologica; 2011 Jun 21; 96(6):801-7. PubMed ID: 21330322
    [Abstract] [Full Text] [Related]

  • 10. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
    Fasano RM, Miller MJ, Chonat S, Stowell SR.
    Transfus Clin Biol; 2019 May 21; 26(2):94-98. PubMed ID: 30837199
    [Abstract] [Full Text] [Related]

  • 11. [Risks associated with transfusions in sickle cell disease: delayed hemolytic transfusion reaction].
    Habibi A, Noizat-Pirenne F.
    Rev Prat; 2014 Oct 21; 64(8):1128-9. PubMed ID: 25510142
    [No Abstract] [Full Text] [Related]

  • 12. Delayed hemolytic transfusion reactions in sickle cell anemia.
    Rao KR, Patel AR.
    South Med J; 1989 Aug 21; 82(8):1034-6. PubMed ID: 2762885
    [Abstract] [Full Text] [Related]

  • 13. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
    Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW.
    Transfusion; 2019 Jun 21; 59(6):1907-1910. PubMed ID: 30768787
    [Abstract] [Full Text] [Related]

  • 14. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease.
    Mekontso Dessap A, Pirenne F, Razazi K, Moutereau S, Abid S, Brun-Buisson C, Maitre B, Michel M, Galacteros F, Bartolucci P, Habibi A.
    Am J Hematol; 2016 Dec 21; 91(12):1181-1184. PubMed ID: 27538126
    [Abstract] [Full Text] [Related]

  • 15. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.
    Gardner K, Hoppe C, Mijovic A, Thein SL.
    Br J Haematol; 2015 Sep 21; 170(6):745-56. PubMed ID: 25967919
    [Abstract] [Full Text] [Related]

  • 16. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
    Madu AJ, Ugwu AO, Efobi C.
    Med Princ Pract; 2021 Sep 21; 30(3):236-243. PubMed ID: 33176303
    [Abstract] [Full Text] [Related]

  • 17. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
    Jasinski S, Glasser CL.
    J Pediatr Hematol Oncol; 2019 Nov 21; 41(8):624-626. PubMed ID: 30179992
    [Abstract] [Full Text] [Related]

  • 18. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
    Ferlis M, Lipato T, Roseff SD, Smith WR.
    Eur J Haematol; 2022 Nov 21; 109(5):586-589. PubMed ID: 35848827
    [Abstract] [Full Text] [Related]

  • 19. Severe delayed hemolytic transfusion reaction secondary to anti-At(a).
    Cash KL, Brown T, Sausais L, Uehlinger J, Reed LJ.
    Transfusion; 1999 Aug 21; 39(8):834-7. PubMed ID: 10504118
    [Abstract] [Full Text] [Related]

  • 20. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
    Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, Galactéros F, Bierling P.
    Haematologica; 2007 Dec 21; 92(12):e132-5. PubMed ID: 18055978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.